Biofrontera Q1 revenue rises on higher Ameluz sales

Biofrontera

14/05/2026 12:40

Corrects EPS in Key Details table to -$0.41 from $0.41

Overview

U.S. biopharmaceutical firm's Q1 revenue rose 17% on higher Ameluz sales and price increases

Adjusted EBITDA loss narrowed year over year, reflecting improved gross margins under new earnout structure

Outlook

Company remains focused on achieving sustained profitability and cash-flow breakeven

Result Drivers

AMELUZ SALES AND PRICING - Revenue growth was primarily driven by a 16% increase in Ameluz units sold and a price increase implemented in Q4 2025

GROSS MARGIN EXPANSION - Gross margin rose to 80% from 62% due to the new earnout structure after the strategic transaction with Biofrontera AG

HIGHER OPERATING EXPENSES - Operating expenses rose due to increased selling and marketing costs, lower sales team turnover, increased legal expenses, and manufacturing costs from the strategic transaction

Company press release: ID:nGNXbvxJNl

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$10.10 mln
$10.25 mln (2 Analysts)
Q1 EPS
-$0.41
Q1 Net Income
-$4.80 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)